MBX Biosciences doses first patient in Phase 3 oPTimize trial of once-weekly canvuparatide for hypoparathyroidism
MBX•Phase 3 trial begins
MBX Biosciences started dosing patients in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism.
The Phase 2 Avail results were previously presented, with one-year follow-up indicating sustained clinical benefit.
Study design and purpose
The Phase 3 study aims to support registration, targeting a therapy that could reduce reliance on standard supplements while keeping calcium controlled.
The global trial plans to enroll about 160 adults, with a 26-week blinded period followed by a 78-week open-label extension.
